Skip to main content
TipRanks
Go Ultimate75% OFF

Beyond Medical Technologies Inc (DOCT) AI Stock Analysis

40 Followers
TSE:DOCT

Beyond Medical Technologies Inc

(CNQX:DOCT)

Select Model
Rating:37Underperform
Price Target:CAD 0.14â–¼(-3.45% Downside)
Action:reiterated
Date:09/06/26

The company faces an existential financial crisis with collapsed revenue, massive losses, and insolvency. While the stock price has recently risen, technical indicators are flashing extreme overbought warnings, suggesting the rally is unsustainable. The negative P/E ratio confirms the lack of earnings power. The overall score is at the minimum due to the combination of fundamental collapse and extreme technical risk.

Positive Factors
Healthcare Technology FocusA defined focus on medical and healthcare-related technology gives the company a clear strategic identity. If execution improves, this specialization could support targeted product development and customer acquisition within a sector where technology adoption can remain structurally relevant.
Negative Factors
Severely Weak Revenue and ProfitabilityMinimal and declining revenue provides little evidence of durable commercial traction, while large operating and net losses show that the current business scale does not support the cost base. Persistent weak earnings limit reinvestment capacity and make a sustainable recovery dependent on improved sales execution.

Beyond Medical Technologies Inc (DOCT) vs. iShares MSCI Canada ETF (EWC)

-80%-60%-40%-20%0%20%40%TSE:DOCT-51.67%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 4.76M
Dividend Yield
―
Average Volume (3M)
3,133
Price to Earnings (P/E)
-0.6
Beta (1Y)
1.29
Revenue Growth
―
EPS Growth
-156.09%
Country
Canada
Employees
3
Sector
Industrials
Sector Strength
63
Industry
Industrial - Pollution & Treatment Controls

Beyond Medical Technologies Inc Business Overview & Revenue Model

Company Description

Republic Technologies Inc. provides Ethereum-based technology services. The company develops Validity Network, an attestation platform that provides cryptographically secure and tamper-resistant assurances of data integrity by anchoring data commitme...

Beyond Medical Technologies Inc Financial Statement Overview

Summary

Financial performance is critically poor. Revenue has collapsed to negative territory, net losses exceed $8M, and the company is technically insolvent with negative equity and over $11M in debt. Operating cash flow is deeply negative, indicating an unsustainable burn rate.

Income Statement

1Very Negative

Balance Sheet

1Very Negative

Cash Flow

1Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue11.48K11.48K000943.42K
Gross Profit11.48K11.48K000-250.00K
EBITDA-1.49M-2.09M0-37.96K-772.91K-1.26M
Net Income-2.04M-2.68M-285-596.00K-1.40M-2.91M
Balance Sheet
Total Assets15.85M15.85M13.80K95.64K608.18K1.95M
Cash, Cash Equivalents and Short-Term Investments2.76M2.76M13.22K64.14K536.75K1.43M
Total Debt11.86M11.86M60.00K30.00K085.09K
Total Liabilities15.71M15.71M634.46K430.35K346.94K413.28K
Stockholders Equity133.53K133.53K-620.66K-334.72K261.25K1.54M
Cash Flow
Free Cash Flow-1.43M-1.70M-109.77K-527.04K-894.01K-1.47M
Operating Cash Flow-1.43M-1.70M-109.77K-527.04K-894.01K-1.40M
Investing Cash Flow-2.02M-677.07K000-467.99K
Financing Cash Flow6.20M5.13M30.00K30.00K02.67M

Beyond Medical Technologies Inc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.14

Price Trends

50DMA0.17Negative
100DMA0.15Negative
200DMA0.16Negative

Market Momentum

MACD-0.01Positive
RSI19.61Positive
STOCH-6.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.17, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 19.61 is Positive, neither overbought nor oversold. The STOCH value of -6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.

Beyond Medical Technologies Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

TSE:DOCT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
TSE:APLTSE:APL44NeutralCAD 3.98M161.090.59%――36.73%
TSE:DOCTTSE:DOCT37UnderperformCAD 4.76M-0.57732.50%――-156.09%

* Industrials Sector Average

Performance Comparison

-50%-25%0%25%TSE:DOCTTSE:APLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:DOCT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:DOCTBeyond Medical Technologies Inc0.14-0.15-51.67%
TSE:APLAppulse Corp0.270.0522.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026